Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew L Frelinger

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Thrombosis and Haemostasis|June 29, 2007
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirinAndrew L Frelinger, Joseph A Jakubowski, Youfu Li, et al.
Thrombosis and Haemostasis|December 11, 2012
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) studyJorge F Saucedo, Dominick J Angiolillo, Roger DeRaad, et al.
European Heart Journal|January 22, 2011
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 TrialDominick J Angiolillo, Juan Jose Badimon, Jorge F Saucedo, et al.
Thrombosis and Haemostasis|September 10, 2021
Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher DiseaseShoshana Revel-Vilk, Mira Naamad, Dafna Frydman, et al.
Journal of the American College of Cardiology|January 17, 2017
Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes MellitusDeepak L Bhatt, Tilo Grosser, Jing-Fei Dong, et al.
Journal of the American College of Cardiology|January 22, 2013
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet functionAndrew L Frelinger, Deepak L Bhatt, Ronald D Lee, et al.
Plos One|August 25, 2016
Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich PlasmaAndrew L Frelinger, Anja J Gerrits, Allen L Garner, et al.
Thrombosis and Haemostasis|June 30, 2011
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44Andrew L Frelinger, Alan D Michelson, Stephen D Wiviott, et al.
Blood|October 17, 2020
Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkersDebra D Pittman, Patrick C Hines, David Beidler, et al.
Thrombosis Research|November 5, 2017
Calpain-1 regulates platelet function in a humanized mouse model of sickle cell diseaseJennifer O Nwankwo, Thomas Gremmel, Anja J Gerrits, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Thrombosis and Haemostasis|June 29, 2007
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirinAndrew L Frelinger, Joseph A Jakubowski, Youfu Li, et al.
Thrombosis and Haemostasis|December 11, 2012
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) studyJorge F Saucedo, Dominick J Angiolillo, Roger DeRaad, et al.
European Heart Journal|January 22, 2011
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 TrialDominick J Angiolillo, Juan Jose Badimon, Jorge F Saucedo, et al.
Thrombosis and Haemostasis|September 10, 2021
Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher DiseaseShoshana Revel-Vilk, Mira Naamad, Dafna Frydman, et al.
Journal of the American College of Cardiology|January 17, 2017
Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes MellitusDeepak L Bhatt, Tilo Grosser, Jing-Fei Dong, et al.
Journal of the American College of Cardiology|January 22, 2013
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet functionAndrew L Frelinger, Deepak L Bhatt, Ronald D Lee, et al.
Plos One|August 25, 2016
Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich PlasmaAndrew L Frelinger, Anja J Gerrits, Allen L Garner, et al.
Thrombosis and Haemostasis|June 30, 2011
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44Andrew L Frelinger, Alan D Michelson, Stephen D Wiviott, et al.
Blood|October 17, 2020
Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkersDebra D Pittman, Patrick C Hines, David Beidler, et al.
Thrombosis Research|November 5, 2017
Calpain-1 regulates platelet function in a humanized mouse model of sickle cell diseaseJennifer O Nwankwo, Thomas Gremmel, Anja J Gerrits, et al.
Pageof 10